Business
Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
Non-dilutive funding extends Ovid’s operational runway; Immedica assumes certain ganaxolone IP costsNEW YORK and STOCKHOLM, Sweden, June 25, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today announced that it has entered into a definitive agreement with Immedica Pharma AB (‘Immedica’), a leading global rare disease company, for the sale of its future
About this update from Ovid Therapeutics Inc.
[{"type":"image","alt":"Ovid Therapeutics Inc.","displaySize":"","headline":null,"caption":"Ovid Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":142,"url":"https://media.zenfs.com/en/globenewswire.com/baa9b4878fad6bda7fe19181be40a802"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/27DLXferaeZxhRE9vCTuYA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/baa9b4878fad6bda7fe19181be40a802","width":300,"height":142}},"lazy":false},{"type":"text","content":"Non-dilutive funding extends Ovid’s operational runway; Immedica assumes certain ganaxolone IP costs","length":100,"tagName":"p"},{"type":"text","content":"NEW YORK and STOCKHOLM, Sweden, June 25, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today announced that it has entered into a definitive agreement with Immedica Pharma AB (‘Immedica’), a leading global rare disease company, for the sale of its future royalties related to sales of ganaxolone outside of China. Under the terms of the agreement, Immedica will pay $7 million in cash to acquire 100% of the royalty rights held by Ovid, further strengthening Immedica’s focus on ganaxolone by acquiring control of additional intellectual property rights.","length":699,"tagName":"p"},{"type":"text","content":"This transaction provides a non-dilutive capital infusion of $7 million to Ovid, which will support the Company’s ongoing operations. In 2024, Ovid recorded approximately $566,000 in ganaxolone royalty revenues. Ovid has not been pursuing development of ganaxolone, and the transaction has no impact to the Company’s current pipeline of programs.","length":346,"tagName":"p"},{"type":"text","content":"In February 2022, Ovid entered into an exclusive patent license agreement with Marinus Pharmaceuticals, Inc.(‘Marinus’) related to the use of ganaxolone in CDKL5 deficiency disorder (CDD). Under that agreement, Ovid was eligible to receive royalties on the sales of ganaxolone for CDD in the United States and Europe. In addition to acquiring future royalty rights related to the use of ganaxolone in CDD, Immedica has entered into an agreement to acquire or license the global ganaxolone intellectual property (IP) portf...